Derived neutrophil lymphocyte ratio may predict benefit from Cisplatin in the advanced biliary cancer: The ABC-02 and BT-22 studies.
Grenader, T Nash, S Plotkin, Y Furuse, J Mizuno, N Okusaka, T Wasan, H Bridgewater, J
Grenader, T
Nash, S
Plotkin, Y
Furuse, J
Mizuno, N
Okusaka, T
Wasan, H
Bridgewater, J
Citations
Altmetric:
Abstract
The superiority of cisplatin and gemcitabine (CisGem) chemotherapy over gemcitabine (Gem) alone in patients with advanced biliary tract cancer (ABC) has been demonstrated in two randomised trials; ABC02 and the Biliary Tract (BT) 22 study. We used a combined dataset from these two trials to investigate the derived neutrophil to lymphocyte ratio (dNLR), which is thought to be a prognostic factor associated with clinical outcomes in several solid tumours, including ABC.
Affiliation
Description
Date
2015-06-02
Publisher
Collections
Keywords
Type
Article
Citation
Derived neutrophil lymphocyte ratio may predict benefit from Cisplatin in the advanced biliary cancer: The ABC-02 and BT-22 studies. 2015: Ann Oncol